US OptionsDetailed Quotes
MREO241115P3500
- 0.00
- 0.000.00%
15min DelayClose Oct 31 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest3.50Strike Price0.00Turnover0.00%IV16.86%PremiumNov 15, 2024Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Mereo BioPharma Stock Discussion
Sign in to post a comment
Double top right now in the 4.40 area. If that doesn't get broken then watch for a pull back. Here are the macro levels to keep an eye on if you are looking for an entry long.
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
Larger Image: tradingview.com...
$Mereo BioPharma (MREO.US)$
2
1
$Mereo BioPharma (MREO.US)$
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
Mereo spikes after mid-stage data for Ultragenyx-partnered bone disorder therapy
$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...
4
$SPDR S&P Biotech ETF (XBI.US)$
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
The biotech sector faced challenges in the previous year, mainly attributed to high inflation and interest rates, particularly impacting small-cap biotech firms in the difficult fundraising environment of summer 2023.
As a consequence, numerous companies experienced a significant drop in their market caps, with some even falling below the 100 million mark, a rarity...
21
3
$Mereo BioPharma (MREO.US)$ LFG!!!!
1
1
No comment yet
Paul Bin Anthony : tq Sir God bless All you need